| Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer ML Disis, DR Wallace, TA Gooley, Y Dang, M Slota, H Lu, AL Coveler, ... Journal of Clinical Oncology 27 (28), 4685-4692, 2009 | 327 | 2009 |
| The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system AL Engel, GE Holt, H Lu Expert review of clinical pharmacology 4 (2), 275-289, 2011 | 213 | 2011 |
| Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer H Lu, V Goodell, ML Disis Journal of proteome research 7 (4), 1388-1394, 2008 | 202 | 2008 |
| VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC H Lu, GN Dietsch, MAH Matthews, Y Yang, S Ghanekar, M Inokuma, ... Clinical cancer research 18 (2), 499-509, 2012 | 186 | 2012 |
| IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice KL Knutson, Y Dang, H Lu, J Lukas, B Almand, E Gad, E Azeke, ML Disis The Journal of Immunology 177 (1), 84-91, 2006 | 181 | 2006 |
| Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells H Lu, Y Yang, E Gad, CA Wenner, A Chang, ER Larson, Y Dang, ... Clinical Cancer Research 17 (1), 67-76, 2011 | 161 | 2011 |
| Immunoediting of cancers may lead to epithelial to mesenchymal transition KL Knutson, H Lu, B Stone, JM Reiman, MD Behrens, CM Prosperi, ... The Journal of Immunology 177 (3), 1526-1533, 2006 | 148 | 2006 |
| Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with Merkel cell carcinoma S Bhatia, NJ Miller, H Lu, NV Longino, D Ibrani, MM Shinohara, DR Byrd, ... Clinical Cancer Research 25 (4), 1185-1195, 2019 | 116 | 2019 |
| Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys J Storek, T Gillespy III, H Lu, A Joseph, MA Dawson, M Gough, J Morris, ... Blood, The Journal of the American Society of Hematology 101 (10), 4209-4218, 2003 | 110 | 2003 |
| TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy H Lu, Y Yang, E Gad, C Inatsuka, CA Wenner, ML Disis, LJ Standish Clinical cancer research 17 (21), 6742-6753, 2011 | 100 | 2011 |
| Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial LG Salazar, H Lu, JL Reichow, JS Childs, AL Coveler, DM Higgins, ... JAMA oncology 3 (7), 969-973, 2017 | 99 | 2017 |
| TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects H Lu Frontiers in immunology 5, 83, 2014 | 97 | 2014 |
| Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor J Ladd, H Lu, AD Taylor, V Goodell, ML Disis, S Jiang Colloids and Surfaces B: Biointerfaces 70 (1), 1-6, 2009 | 93 | 2009 |
| Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade H Lu, WM Wagner, E Gad, Y Yang, H Duan, LM Amon, N Van Denend, ... The Journal of Immunology 184 (9), 5360-5367, 2010 | 90 | 2010 |
| First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1 N Somaiah, MS Block, JW Kim, GI Shapiro, KT Do, P Hwu, JP Eder, ... Clinical Cancer Research 25 (19), 5808-5817, 2019 | 79 | 2019 |
| Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) J Storek, Z Zhao, E Lin, T Berger, PA McSweeney, RA Nash, Y Akatsuka, ... Clinical immunology 113 (3), 285-298, 2004 | 74 | 2004 |
| Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera H Lu, J Ladd, Z Feng, M Wu, V Goodell, SJ Pitteri, CI Li, R Prentice, ... Cancer prevention research 5 (8), 1036-1043, 2012 | 70 | 2012 |
| TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway Y Xing, Y Liu, T Liu, Q Meng, H Lu, W Liu, J Hu, C Li, M Cao, S Yan, ... Cell communication and signaling 16, 1-15, 2018 | 67 | 2018 |
| miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC X Wang, Q Meng, W Qiao, R Ma, W Ju, J Hu, H Lu, J Cui, Z Jin, Y Zhao, ... Stem Cell Research & Therapy 9, 1-14, 2018 | 66 | 2018 |
| Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity GN Dietsch, H Lu, Y Yang, C Morishima, LQ Chow, ML Disis, ... PloS one 11 (2), e0148764, 2016 | 65 | 2016 |
Tomas KalinaCharles University in Prague - 2nd Faculty of Medicine在 lfmotol.cuni.cz 的电子邮件经过验证
